関連する実験動画
Updated: Jun 29, 2025

10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
DCAF5をターゲットにすることで,SWI/SNFを安定させることで,SMARCB1変異がんを抑制する
Sandi Radko-Juettner1,2, Hong Yue3,4, Jacquelyn A Myers1
1Division of Molecular Oncology, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Nature
|March 28, 2024
まとめ
がんにおけるSMARCB1腫瘍抑制機能の喪失は,突然変異によって直接引き起こされるのではなく,DCAF5を退廃させるSWI/ SNF複合体によって引き起こされる. DCAF5をターゲットにすることで,SWI/SNF機能を回復させることで,がん状態を逆転させることができます.
科学分野:
- 腫瘍学
- 分子生物学
- 遺伝学
背景:
- 腫瘍抑制機能の喪失は,腫瘍遺伝子の活性化とは異なり,標的タンパク質が存在しないため,治療上の課題となる.
- SMARCB1 (SWI/ SNFサブユニット) 変異がんは,これらのクロマチン再構成複合体の不活性化によって引き起こされる致命的な悪性腫瘍です.
研究 の 目的:
- SMARCB1変異ががんに及ぼすメカニズム的影響を調査する.
- SMARCB1変異がんの治療上の脆弱性を特定する.
主な方法:
- ほぼ全ゲノムCRISPRスクリーンで14のSMARCB1変異細胞系を利用した.
- 癌細胞生存とSWI/SNF複合体の安定性におけるDDB1- CUL4関連因子5 (DCAF5) の役割を調査した.
主要な成果:
- SMARCB1変異性がんの生存に不可欠である DCAF5 を特定した.
- DCAF5は,SMARCB1が欠けると不完全なSWI/SNF複合体を分解することを実証した.
- DCAF5の減少は,SMARCB1欠乏したSWI/SNF複合体を救出し,遺伝子発現を回復し,がんの表型をin vitroおよびin vivoで逆転させることが示された.
結論:
- この文脈での癌は,SMARCB1の喪失からではなく,SWI/SNF複合体のDCAF5媒介による分解から生じる.
- DCAF5のようなユビキチン媒介質の品質管理因子を治療的に標的にすることは,腫瘍抑制複合体の障害によって引き起こされる悪性腫瘍を逆転させるための潜在的な戦略を提供します.
関連する概念動画
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K

